In Vitro Activity of Iclaprim against Methicillin-Resistant Staphylococcus aureus Nonsusceptible to Daptomycin, Linezolid, or Vancomycin: A Pilot Study

Figure 1

Iclaprim time-kill curves against MRSA isolates nonsusceptible to linezolid, resistant to vancomycin, and nonsusceptible to daptomycin, 2x, 4x, and 8x MICs were used for all antibiotics. (a) MRSA, linezolid nonsusceptible strain (MIC ≥ 8 µg/mL), ATCC 986537, NRS271. (A) 2x MIC. (B) 4x MIC. (C) 8x MIC. Iclaprim showed significantly lower CFU at 2 h, 4 h, 8 h, and 24 h compared to control, vancomycin, and linezolid (; one-way ANOVA with Tukey’s post hoc test). (b) MRSA, vancomycin-resistant strain (MIC ≥ 32 µg/mL), ATCC 1409053, vanA positive. (A) 2x MIC. (B) 4x MIC. (C) 8x MIC. Iclaprim showed significantly lower CFU at 4 h, 8 h, and 24 h compared to control, vancomycin, and linezolid (; one-way ANOVA with Tukey’s post hoc test). (c) MRSA, daptomycin-resistant strain (MIC ≥ 4 µg/mL) (clinical isolate). (A) 2x MICs. (B) 4x MIC. (C) 8x MIC. Iclaprim showed significantly lower CFU at 4 h, 8 h, and 24 h compared to control, daptomycin, and linezolid (; one-way ANOVA with Tukey’s post hoc test).

(a)

(b)

(c)